COLA Joins CDC Preparedness Effort

COLA is honored to be one of the signatories for the CDC’s Memorandum of Understanding (MOU) for collaboration to enhance diagnostic surge testing capacity for public health emergencies (PHEs). The MOU states that along with the CDC, organizations will work together to enhance testing capacity to respond to pandemics, outbreaks of new pathogens and other…

A New Year Message From COLA

As 2023 draws to a close, we reflect on the successes of the year and the possibilities of the future. COLA is immersed in not only the continued focus on high quality laboratory results, but also the future of the laboratory industry.    Our commitment to excellence is reinforced by our ongoing collaboration with the Workforce…

Understanding Viral Hemorrhagic Fevers: A Brief Overview

The Complex World of Viral Hemorrhagic Fevers  Viral hemorrhagic fevers (VHFs) represent a diverse spectrum of diseases impacting both animals and humans. VHFs are caused by five distinct families of RNA viruses: Filoviridae, Flaviviridae, Rhabdoviridae, Arenaviridae and Hantaviridae. These conditions manifest a wide range of symptoms, often marked by bleeding or hemorrhaging. The disease can…

Overseeing Gain of Function Research in the U.S.: New Insights in the Wake of COVID-19 Revelations (Part 5)

Welcome to the final part of our series on Gain of Function Research (GOFR). This chapter highlights the National Science Advisory Board for Biosecurity’s (NSABB) newest recommendations, which seek to mitigate biosecurity and biosafety risks while advancing crucial research on potential pandemic pathogens. The COVID-19 pandemic, with conjectures about a potential laboratory leak, has reinvigorated…